Show simple item record

dc.contributor.authorBAHADORİ, FATEMEH
dc.contributor.authorBuyuk, Ayse Seyma
dc.contributor.authorKOZANOĞLU, Ahmed Serdar
dc.contributor.authorEskandari, Zahra
dc.contributor.authorANKARALI, HANDAN
dc.contributor.authorKepekci Tekkeli, Serife Evrim
dc.contributor.authorNur Kaleli, Humeyra
dc.contributor.authorKOÇYİĞİT, ABDÜRRAHİM
dc.date.accessioned2020-01-14T21:00:09Z
dc.date.available2020-01-14T21:00:09Z
dc.date.issued2019-07-01T00:00:00Z
dc.identifier.urihttps://openaccess.bezmialem.edu.tr/handle/20.500.12645/12765
dc.description.abstractObjective: Celecoxib (CLX), brand named Celebrex, which belongs to non-steroidal anti-inflammatory drugs family, selectively inhibits the cytokine related cyclooxygenase-2 isoenzyme and thus, possesses less gastrointestinal side effects, have shown to cause stroke, myocard infarction and even death in some cases. In this study we aimed to target inflammation site using CLX uploaded nano-micelles (nano-CLX) made of poly (lactic-co-glycolic) acid (PLGA) to protect other tissues from its side effects.
dc.subjectBAHADORİ F., Buyuk A. S. , KOZANOĞLU A. S. , Eskandari Z., ANKARALI H., Kepekci Tekkeli S. E. , Nur Kaleli H., KOÇYİĞİT A., -Preparation and Evaluation of Inflammation Targeted Nano-micellar Formulation of Celecoxib-, BEZMIALEM SCIENCE, cilt.7, ss.208-214, 2019
dc.titlePreparation and Evaluation of Inflammation Targeted Nano-micellar Formulation of Celecoxib
dc.typeArticle
dc.identifier.wosWOS:000499482100007
dc.identifier.doi10.14235/bas.galenos.2018.2673
local.publication.isinternational1
dc.contributor.institutionauthorKOÇYİĞİT, ABDÜRRAHİM


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record